Skip to main content
Top
Published in: Annals of Surgical Oncology 12/2011

Open Access 01-11-2011 | Colorectal Cancer

Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature

Authors: Sabine Venderbosch, MSc, Johannes H. de Wilt, MD, PhD, Steven Teerenstra, PhD, Olaf J. Loosveld, MD, PhD, Aart van Bochove, MD, PhD, Harm A. Sinnige, MD, PhD, Geert-Jan M. Creemers, MD, PhD, Margot E. Tesselaar, MD, PhD, Linda Mol, MSc, Cornelis J. A. Punt, MD, PhD, Miriam Koopman, MD, PhD

Published in: Annals of Surgical Oncology | Issue 12/2011

Login to get access

Abstract

Background

In patients with metastatic colorectal cancer (mCRC) with an asymptomatic primary tumor, there is no consensus on the indication for resection of the primary tumor.

Methods

A retrospective analysis was performed on the outcome of stage IV colorectal cancer (CRC) patients with or without resection of the primary tumor treated in the phase III CAIRO and CAIRO2 studies. A review of the literature was performed.

Results

In the CAIRO and CAIRO2 studies, 258 and 289 patients had undergone a primary tumor resection and 141 and 159 patients had not, respectively. In the CAIRO study, a significantly better median overall survival and progression-free survival was observed for the resection compared to the nonresection group, with 16.7 vs. 11.4 months [P < 0.0001, hazard ratio (HR) 0.61], and 6.7 vs. 5.9 months (P = 0.004; HR 0.74), respectively. In the CAIRO2 study, median overall survival and progression-free survival were also significantly better for the resection compared to the nonresection group, with 20.7 vs. 13.4 months (P < 0.0001; HR 0.65) and 10.5 vs. 7.8 months (P = 0.014; HR 0.78), respectively. These differences remained significant in multivariate analyses. Our review identified 22 nonrandomized studies, most of which showed improved survival for mCRC patients who underwent resection of the primary tumor.

Conclusions

Our results as well as data from literature indicate that resection of the primary tumor is a prognostic factor for survival in stage IV CRC patients. The potential bias of these results warrants prospective studies on the value of resection of primary tumor in this setting; such studies are currently being planned.
Literature
1.
go back to reference Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol. 2007;8:898–911.PubMedCrossRef Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol. 2007;8:898–911.PubMedCrossRef
2.
go back to reference Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677–83.PubMedCrossRef Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677–83.PubMedCrossRef
3.
go back to reference O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420–5.PubMedCrossRef O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420–5.PubMedCrossRef
4.
go back to reference Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26:5721–7.PubMedCrossRef Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26:5721–7.PubMedCrossRef
5.
go back to reference Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209–14.PubMedCrossRef Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209–14.PubMedCrossRef
6.
go back to reference Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer: what have we learned? Eur J Cancer. 2009;45:1935–49.PubMedCrossRef Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer: what have we learned? Eur J Cancer. 2009;45:1935–49.PubMedCrossRef
7.
go back to reference Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374–9.PubMedCrossRef Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374–9.PubMedCrossRef
8.
go back to reference Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009;361:98–9.PubMedCrossRef Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009;361:98–9.PubMedCrossRef
9.
go back to reference Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of Surveillance, Epidemiology, and End Results data, 1988 to 2000. Ann Surg Oncol. 2005;12:637–45.PubMedCrossRef Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of Surveillance, Epidemiology, and End Results data, 1988 to 2000. Ann Surg Oncol. 2005;12:637–45.PubMedCrossRef
10.
go back to reference Joffe J, Gordon PH. Palliative resection for colorectal carcinoma. Dis Colon Rectum. 1981;24:355–60.PubMedCrossRef Joffe J, Gordon PH. Palliative resection for colorectal carcinoma. Dis Colon Rectum. 1981;24:355–60.PubMedCrossRef
11.
go back to reference Stearns MW Jr, Binkley GE. Palliative surgery for cancer of the rectum and colon. Cancer. 1954;7:1016–9.PubMedCrossRef Stearns MW Jr, Binkley GE. Palliative surgery for cancer of the rectum and colon. Cancer. 1954;7:1016–9.PubMedCrossRef
12.
go back to reference Modlin J, Walker HS. Palliative resections in cancer of the colon and rectum. Cancer. 1949;2:767–76.PubMedCrossRef Modlin J, Walker HS. Palliative resections in cancer of the colon and rectum. Cancer. 1949;2:767–76.PubMedCrossRef
13.
go back to reference Costi R, Mazzeo A, Di Mauro D, et al. Palliative resection of colorectal cancer: does it prolong survival? Ann Surg Oncol. 2007;14:2567–76.PubMedCrossRef Costi R, Mazzeo A, Di Mauro D, et al. Palliative resection of colorectal cancer: does it prolong survival? Ann Surg Oncol. 2007;14:2567–76.PubMedCrossRef
14.
go back to reference Sorbye H, Kohne CH, Sargent DJ, Glimelius B. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol. 2007;18:1666–72.PubMedCrossRef Sorbye H, Kohne CH, Sargent DJ, Glimelius B. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol. 2007;18:1666–72.PubMedCrossRef
15.
go back to reference Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007;370:135–42.PubMedCrossRef Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007;370:135–42.PubMedCrossRef
16.
go back to reference Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563–72.PubMedCrossRef Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563–72.PubMedCrossRef
17.
go back to reference Koopman M, Antonini NF, Douma J, et al. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer: an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. Ann Oncol. 2006;17:1523–8.PubMedCrossRef Koopman M, Antonini NF, Douma J, et al. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer: an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. Ann Oncol. 2006;17:1523–8.PubMedCrossRef
18.
go back to reference Tol J, Koopman M, Rodenburg CJ, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer: the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol. 2008;19:734–8.PubMedCrossRef Tol J, Koopman M, Rodenburg CJ, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer: the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol. 2008;19:734–8.PubMedCrossRef
19.
go back to reference Aslam MI, Kelkar A, Sharpe D, Jameson JS. Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers. Int J Surg. 2010;8:305–13.PubMedCrossRef Aslam MI, Kelkar A, Sharpe D, Jameson JS. Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers. Int J Surg. 2010;8:305–13.PubMedCrossRef
20.
go back to reference Bajwa A, Blunt N, Vyas S, et al. Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. Eur J Surg Oncol. 2009;35:164–7.PubMedCrossRef Bajwa A, Blunt N, Vyas S, et al. Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. Eur J Surg Oncol. 2009;35:164–7.PubMedCrossRef
21.
go back to reference Beham A, Rentsch M, Pullmann K, et al. Survival benefit in patients after palliative resection vs. non-resection colon cancer surgery. World J Gastroenterol. 2006;12:6634–8.PubMed Beham A, Rentsch M, Pullmann K, et al. Survival benefit in patients after palliative resection vs. non-resection colon cancer surgery. World J Gastroenterol. 2006;12:6634–8.PubMed
22.
go back to reference Chan TW, Brown C, Ho CC, Gill S. Primary tumor resection in patients presenting with metastatic colorectal cancer: analysis of a provincial population-based cohort. Am J Clin Oncol. 2010;33:52–5.PubMedCrossRef Chan TW, Brown C, Ho CC, Gill S. Primary tumor resection in patients presenting with metastatic colorectal cancer: analysis of a provincial population-based cohort. Am J Clin Oncol. 2010;33:52–5.PubMedCrossRef
23.
go back to reference Seo GJ, Park JW, Yoo SB, et al. Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer. J Surg Oncol. 2010;102:94–9.PubMedCrossRef Seo GJ, Park JW, Yoo SB, et al. Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer. J Surg Oncol. 2010;102:94–9.PubMedCrossRef
24.
go back to reference Evans MD, Escofet X, Karandikar SS, Stamatakis JD. Outcomes of resection and non-resection strategies in management of patients with advanced colorectal cancer. World J Surg Oncol. 2009;7:28.PubMedCrossRef Evans MD, Escofet X, Karandikar SS, Stamatakis JD. Outcomes of resection and non-resection strategies in management of patients with advanced colorectal cancer. World J Surg Oncol. 2009;7:28.PubMedCrossRef
25.
go back to reference Galizia G, Lieto E, Orditura M, et al. First-line chemotherapy vs. bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg. 2008;143:352–8.PubMedCrossRef Galizia G, Lieto E, Orditura M, et al. First-line chemotherapy vs. bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg. 2008;143:352–8.PubMedCrossRef
26.
go back to reference Kaufman MS, Radhakrishnan N, Roy R, et al. Influence of palliative surgical resection on overall survival in patients with advanced colorectal cancer: a retrospective single institutional study. Colorectal Dis. 2008;10:498–502.PubMedCrossRef Kaufman MS, Radhakrishnan N, Roy R, et al. Influence of palliative surgical resection on overall survival in patients with advanced colorectal cancer: a retrospective single institutional study. Colorectal Dis. 2008;10:498–502.PubMedCrossRef
27.
go back to reference Konyalian VR, Rosing DK, Haukoos JS, et al. The role of primary tumour resection in patients with stage IV colorectal cancer. Colorectal Dis. 2007;9:430–7.PubMedCrossRef Konyalian VR, Rosing DK, Haukoos JS, et al. The role of primary tumour resection in patients with stage IV colorectal cancer. Colorectal Dis. 2007;9:430–7.PubMedCrossRef
28.
go back to reference Law WL, Chan WF, Lee YM, Chu KW. Non-curative surgery for colorectal cancer: critical appraisal of outcomes. Int J Colorectal Dis. 2004;19:197–202.PubMedCrossRef Law WL, Chan WF, Lee YM, Chu KW. Non-curative surgery for colorectal cancer: critical appraisal of outcomes. Int J Colorectal Dis. 2004;19:197–202.PubMedCrossRef
29.
go back to reference Liu SK, Church JM, Lavery IC, Fazio VW. Operation in patients with incurable colon cancer—is it worthwhile? Dis Colon Rectum. 1997;40:11–4.PubMedCrossRef Liu SK, Church JM, Lavery IC, Fazio VW. Operation in patients with incurable colon cancer—is it worthwhile? Dis Colon Rectum. 1997;40:11–4.PubMedCrossRef
30.
go back to reference Makela J, Haukipuro K, Laitinen S, Kairaluoma MI. Palliative operations for colorectal cancer. Dis Colon Rectum. 1990;33:846–50.PubMedCrossRef Makela J, Haukipuro K, Laitinen S, Kairaluoma MI. Palliative operations for colorectal cancer. Dis Colon Rectum. 1990;33:846–50.PubMedCrossRef
31.
go back to reference Michel P, Roque I, Di Fiore F, et al. Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? Gastroenterol Clin Biol. 2004;28:434–7.PubMedCrossRef Michel P, Roque I, Di Fiore F, et al. Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? Gastroenterol Clin Biol. 2004;28:434–7.PubMedCrossRef
32.
go back to reference Mik M, Dziki L, Galbfach P, Trzcinski R, Sygut A, Dziki A. Resection of the primary tumour or other palliative procedures in incurable stage IV colorectal cancer patients? Colorectal Dis. 2010;12:e61–67.PubMedCrossRef Mik M, Dziki L, Galbfach P, Trzcinski R, Sygut A, Dziki A. Resection of the primary tumour or other palliative procedures in incurable stage IV colorectal cancer patients? Colorectal Dis. 2010;12:e61–67.PubMedCrossRef
33.
go back to reference Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg. 2003;196:722–8.PubMedCrossRef Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg. 2003;196:722–8.PubMedCrossRef
34.
go back to reference Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol. 1999;6:651–7.PubMedCrossRef Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol. 1999;6:651–7.PubMedCrossRef
35.
go back to reference Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol. 2005;89:211–7.PubMedCrossRef Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol. 2005;89:211–7.PubMedCrossRef
36.
go back to reference Tebbutt NC, Norman AR, Cunningham D, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52:568–73.PubMedCrossRef Tebbutt NC, Norman AR, Cunningham D, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52:568–73.PubMedCrossRef
37.
go back to reference Yun HR, Lee WY, Lee WS, Cho YB, Yun SH, Chun HK. The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient’s status. Int J Colorectal Dis. 2007;22:1301–10.PubMedCrossRef Yun HR, Lee WY, Lee WS, Cho YB, Yun SH, Chun HK. The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient’s status. Int J Colorectal Dis. 2007;22:1301–10.PubMedCrossRef
38.
go back to reference Frago R, Kreisler E, Biondo S, Salazar R, Dominguez J, Escalante E. Outcomes in the management of obstructive unresectable stage IV colorectal cancer. Eur J Surg Oncol. 2010;36:1187–94.PubMedCrossRef Frago R, Kreisler E, Biondo S, Salazar R, Dominguez J, Escalante E. Outcomes in the management of obstructive unresectable stage IV colorectal cancer. Eur J Surg Oncol. 2010;36:1187–94.PubMedCrossRef
39.
go back to reference Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg. 2005;92:1155–60.PubMedCrossRef Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg. 2005;92:1155–60.PubMedCrossRef
40.
go back to reference Rosen SA, Buell JF, Yoshida A, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg. 2000;135:530–4.PubMedCrossRef Rosen SA, Buell JF, Yoshida A, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg. 2000;135:530–4.PubMedCrossRef
41.
go back to reference Kuo LJ, Leu SY, Liu MC, Jian JJ, Hongiun CS, Chen CM. How aggressive should we be in patients with stage IV colorectal cancer? Dis Colon Rectum. 2003;46:1646–52.PubMedCrossRef Kuo LJ, Leu SY, Liu MC, Jian JJ, Hongiun CS, Chen CM. How aggressive should we be in patients with stage IV colorectal cancer? Dis Colon Rectum. 2003;46:1646–52.PubMedCrossRef
42.
go back to reference Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg. 2010;34:797–807.PubMedCrossRef Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg. 2010;34:797–807.PubMedCrossRef
43.
go back to reference van Steenbergen LN, Elferink MA, Krijnen P, et al. Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in the Netherlands, 1989–2006. Ann Oncol. 2010;21:2206–12.PubMedCrossRef van Steenbergen LN, Elferink MA, Krijnen P, et al. Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in the Netherlands, 1989–2006. Ann Oncol. 2010;21:2206–12.PubMedCrossRef
44.
go back to reference Meulenbeld HJ, van Steenbergen LN, Janssen-Heijnen ML, Lemmens VE, Creemers GJ. Significant improvement in survival of patients presenting with metastatic colon cancer in the south of the Netherlands from 1990 to 2004. Ann Oncol. 2008;19:1600–4.PubMedCrossRef Meulenbeld HJ, van Steenbergen LN, Janssen-Heijnen ML, Lemmens VE, Creemers GJ. Significant improvement in survival of patients presenting with metastatic colon cancer in the south of the Netherlands from 1990 to 2004. Ann Oncol. 2008;19:1600–4.PubMedCrossRef
45.
go back to reference Peeters CF, Westphal JR, de Waal RM, Ruiter DJ, Wobbes T, Ruers TJ. Vascular density in colorectal liver metastases increases after removal of the primary tumor in human cancer patients. Int J Cancer. 2004;112:554–9.PubMedCrossRef Peeters CF, Westphal JR, de Waal RM, Ruiter DJ, Wobbes T, Ruers TJ. Vascular density in colorectal liver metastases increases after removal of the primary tumor in human cancer patients. Int J Cancer. 2004;112:554–9.PubMedCrossRef
46.
go back to reference Peeters CF, de Waal RM, Wobbes T, Westphal JR, Ruers TJ. Outgrowth of human liver metastases after resection of the primary colorectal tumor: a shift in the balance between apoptosis and proliferation. Int J Cancer. 2006;119:1249–53.PubMedCrossRef Peeters CF, de Waal RM, Wobbes T, Westphal JR, Ruers TJ. Outgrowth of human liver metastases after resection of the primary colorectal tumor: a shift in the balance between apoptosis and proliferation. Int J Cancer. 2006;119:1249–53.PubMedCrossRef
47.
go back to reference Scheer MG, Stollman TH, Vogel WV, Boerman OC, Oyen WJ, Ruers TJ. Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med. 2008;49:887–91.PubMedCrossRef Scheer MG, Stollman TH, Vogel WV, Boerman OC, Oyen WJ, Ruers TJ. Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med. 2008;49:887–91.PubMedCrossRef
48.
go back to reference Sarela AI, Guthrie JA, Seymour MT, Ride E, Guillou PJ, O’Riordain DS. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg. 2001;88:1352–6.PubMedCrossRef Sarela AI, Guthrie JA, Seymour MT, Ride E, Guillou PJ, O’Riordain DS. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg. 2001;88:1352–6.PubMedCrossRef
49.
go back to reference Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27:3379–84.PubMedCrossRef Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27:3379–84.PubMedCrossRef
50.
go back to reference Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol. 2008;19:1829–35.PubMedCrossRef Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol. 2008;19:1829–35.PubMedCrossRef
Metadata
Title
Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature
Authors
Sabine Venderbosch, MSc
Johannes H. de Wilt, MD, PhD
Steven Teerenstra, PhD
Olaf J. Loosveld, MD, PhD
Aart van Bochove, MD, PhD
Harm A. Sinnige, MD, PhD
Geert-Jan M. Creemers, MD, PhD
Margot E. Tesselaar, MD, PhD
Linda Mol, MSc
Cornelis J. A. Punt, MD, PhD
Miriam Koopman, MD, PhD
Publication date
01-11-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1951-5

Other articles of this Issue 12/2011

Annals of Surgical Oncology 12/2011 Go to the issue